These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 9045355)

  • 1. [Virus in hemophilia: current status and future perspectives].
    Aguilar C; Félix Lucía J
    Sangre (Barc); 1996 Apr; 41(2):141-5. PubMed ID: 9045355
    [No Abstract]   [Full Text] [Related]  

  • 2. Has hepatitis A virus been transmitted by clotting factor concentrates among hemophiliacs in the United States?
    Mosley JW
    Vox Sang; 1994; 67 Suppl 4():12-5; discussion 24-6. PubMed ID: 7831863
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatitis A virus sequence detected in clotting factor concentrates associated with disease transmission.
    Robertson BH; Alter MJ; Bell BP; Evatt B; McCaustland KA; Shapiro CN; Sinha SD; Souci JM
    Biologicals; 1998 Jun; 26(2):95-9. PubMed ID: 9811512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation of viral safety of a high-purity human factor VIII concentrate submitted to 2 specific virus inactivation treatments (FANDHI)].
    Ristol P; Gensana M; Fernández J; Massot M; Biescas H; Darling A; Jorquera JI; Vericat F
    Sangre (Barc); 1996 Apr; 41(2):131-6. PubMed ID: 9045353
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Review of the hepatitis A epidemics in hemophiliacs in Europe.
    Vermylen J; Peerlinck K
    Vox Sang; 1994; 67 Suppl 4():8-11; discussion 24-6. PubMed ID: 7831867
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Virology of the hepatitis A epidemic in Italy.
    Purcell RH; Mannucci PM; Gdovin S; Gringeri A; Colombo M; Mele A; Schinaia N; Ciavarella N; Emerson SU
    Vox Sang; 1994; 67 Suppl 4():2-7; discussion 24-6. PubMed ID: 7831866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical evaluation of viral safety of coagulation factor VIII and IX concentrates.
    Mannucci PM
    Vox Sang; 1993; 64(4):197-203. PubMed ID: 8517048
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Viral safety of hemoderivatives: in search of zero risk].
    Hernández JM; Tusell JM
    Sangre (Barc); 1996 Apr; 41(2):97-100. PubMed ID: 9045365
    [No Abstract]   [Full Text] [Related]  

  • 9. [Transmission of hepatitis C by factor concentrates].
    Aguilar C; Lucía JF
    Sangre (Barc); 1996 Apr; 41(2):160-1. PubMed ID: 9045360
    [No Abstract]   [Full Text] [Related]  

  • 10. Successful clinical use of a plasma-derived, dual virus inactivated factor VII concentrate incorporating solvent-detergent and dry heat treatment.
    Smith MP; Rice KM; Savidge GF
    Thromb Haemost; 1997 Feb; 77(2):406-7. PubMed ID: 9157608
    [No Abstract]   [Full Text] [Related]  

  • 11. Clinical spectrum of viral infections in hemophilic patients.
    Telfer MC
    Hematol Oncol Clin North Am; 1992 Oct; 6(5):1047-56. PubMed ID: 1328142
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outbreaks of hepatitis A and emergence of new AIDS-associated agents: the need to add terminal 100 degrees C dry-heat sterilization to factor VIII and factor IX concentrates.
    Guillaume TA
    Vox Sang; 1993; 65(2):158. PubMed ID: 8212671
    [No Abstract]   [Full Text] [Related]  

  • 13. Purity of concentrates for substitution therapy: acceptable and undesirable contaminants--Madrid 1978.
    Scand J Haematol Suppl; 1980; 35():65-89. PubMed ID: 6770460
    [No Abstract]   [Full Text] [Related]  

  • 14. [Current status of viral safety of virus inactivated factor VIII and IX concentrates in treatment of hemophilia].
    Pollmann H
    Infusionsther Transfusionsmed; 1994 Aug; 21 Suppl 1():80-3. PubMed ID: 8000261
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Why prescribe highly purified factor VIII and IX concentrates?
    Berntorp E
    Vox Sang; 1996; 70(2):61-8. PubMed ID: 8801765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Improvement in anti-hemophilic preparations and arts problems. 1. Heat-treated concentrates].
    Ikematsu S; Yorifuji H; Arai M; Fukutake K
    Rinsho Ketsueki; 1988 May; 29(5):628-34. PubMed ID: 3145993
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of HIV-1 infection on CD4 cells in a hemophilia cohort.
    Green D; Deutsche J; Tang M; Goldsmith J
    Haematologica; 1990; 75 Suppl 5():132-41. PubMed ID: 1982277
    [No Abstract]   [Full Text] [Related]  

  • 18. [Improvement in anti-hemophilic preparations and its problems. 7. Present status and future aspect of anti-hemophilic preparations].
    Kamiya T
    Rinsho Ketsueki; 1988 May; 29(5):666-70. PubMed ID: 3145998
    [No Abstract]   [Full Text] [Related]  

  • 19. Virus infection and clotting factor concentrates.
    Evans DI
    Lancet; 1995 May; 345(8959):1247-8. PubMed ID: 7739337
    [No Abstract]   [Full Text] [Related]  

  • 20. Viral safety of plasma-derived factor VIII and IX concentrates.
    Ludlam CA
    Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.